These findings suggest that NOX2 and BTG2 may have unique value in assessing the prognosis of ESCC patients, and their combination with clinical pathological factors could provide a more accurate evaluation of prognosis for ESCC patients. The gene discussed is CYBB; the disease is esophageal squamous cell carcinoma.